Oramed Pharmaceuticals, Inc. (ORMP) is up 11.21% Thursday In Premarket Trading

Thursday, February 22, 2024 06:39 AM | InvestorsObserver Analysts

Mentioned in this article

Oramed Pharmaceuticals, Inc. (ORMP) has gained Thursday morning, with the stock climbing 11.21% in pre-market trading to 3.57. ORMP's short-term technical score of 44 indicates that the stock has traded less bullishly over the last month than 56% of stocks on the market. In the Biotechnology industry, which ranks 109 out of 146 industries, Oramed Pharmaceuticals, Inc. ranks higher than 61% of stocks. Oramed Pharmaceuticals, Inc. has risen 45.25% over the past month, closing at $2.27 on January 25. During this period of time, the stock fell as low as $2.27 and as high as $3.29. ORMP has an average analyst recommendation of Sell. The company has an average price target of $4.25.

ORMP has an Overall Score of 54. Find out what this means to you and get the rest of the rankings on ORMP!
Oramed Pharmaceuticals, Inc. has a Long-Term Technical rank of 68. This means that trading over the last 200 trading days has placed the company in the upper half of stocks with 32% of the market scoring higher. In the Biotechnology industry which is number 70 by this metric, ORMP ranks better than 70% of stocks.

Important Dates for Investors in ORMP:

-Oramed Pharmaceuticals, Inc. is set to release earnings on 2024-03-04. Over the last 12 months, the company has reported EPS of $-0.41. -We do not have a set dividend date for Oramed Pharmaceuticals, Inc. at this time. Click Here To Get The Full Report on Oramed Pharmaceuticals, Inc. (ORMP)

Share this article: